Glucose-capped gold nanoparticles (Glu-GNPs) have been used to improve cellular targeting and radio-sensitization. In this study, we explored the mechanism of Glu-GNP enhanced radiation sensitivity in radiation-resistant human prostate cancer cells. Cell survival and proliferation were measured using MTT and clonogenic assay. Flow cytometry with staining by propidium iodide (PI) was performed to study the cell cycle changes induced by Glu-GNPs, and western blotting was used to determine the expression of p53 and cyclin proteins that correlated to cell cycle regulation. With 2 Gy of ortho-voltage irradiation, Glu-GNP showed a 1.5-2.0 fold enhancement in growth inhibition when compared to x-rays alone. Comparing the cell cycle change, Glu-GNPs induced acceleration in the G0/G1 phase and accumulation of cells in the G2/M phase at 29.8% versus 18.4% for controls at 24 h. G2/M arrest was accompanied by decreased expression of p53 and cyclin A, and increased expression of cyclin B1 and cyclin E. In conclusion, Glu-GNPs trigger activation of the CDK kinases leading to cell cycle acceleration in the G0/G1 phase and accumulation in the G2/M phase. This activation is accompanied by a striking sensitization to ionizing radiation, which may have clinical implications.
Introduction
Nanotechnology is an emerging technique for improved cellular targeting and radio-sensitization. Nanoparticles (NPs) are widely used to treat cancer. Using structural modification, NPs can be used as delivery vehicles to carry chemotherapeutic agents or radio-sensitizers to malignant cells [1] . NPs can be semiconducting, magnetic or metallic. Semiconductor agents, such as antibodies and DNA probes, has the potential to provide a sensitive and specific means to track tissue specific targets, monitor the progress of cancers, and measure the effects of therapeutic treatments [10] .
Noble metal-based nanoparticles can kill cancer cells synergistically with conventionally used radiotherapy or phototherapy. An animal study involving 25 mice with tumors ranging in size from 3.0 to 5.5 mm [11] showed enhancement of radiation when GNPs were administered prior to treatment. Similar enhancements were also reported in other animal experiments. Specifically, after intravenous injection, gold particles were shown to accumulate in implanted tumors and to enhance the radiation response with little effect on surrounding normal tissues [11] [12] [13] [14] . In addition, x-ray sensitive hybrid nanoparticles can bind themselves to targeted cells through trans-membrane ligands on the cell surface, enter the cytoplasm and result in enhanced cytotoxicity secondary to the photoelectric effect of external beam radiation [15] [16] [17] .
In our recent study, glucose-capped gold nanoparticles (Glu-GNPs) showed significantly increased cellular uptake compared to neutral nanoparticles [18] . Cytoplasmic uptake of Glu-GNP followed by 2 Gy of ortho-voltage irradiation resulted in significant growth inhibition in prostate cancer cells. Glu-GNPs showed a 1.5-2.0 fold enhancement in growth inhibition when compared to GNPs alone. Although we have demonstrated that GNPs can significantly enhance radiosensitivity in prostate cancer treatment [19] , the mechanism of this enhancement has not been thoroughly investigated. To gain further insight into the mechanism of action of GNPs, and to more completely define the spectrum of GNP anticancer activity, we investigated the effects of GNPs on cell cycle regulation and how this affects radio-sensitivity. To accomplish this, we studied the kinetic changes to the cell cycle induced by Glu-GNPs, and then used these kinetic characteristics to guide GNP radiotherapy to achieve optimal efficiency. We report here that GNPs accumulated in prostate cancer DU-145 cells at the G2/M phase via the activation of both checkpoint kinases (CDK1 and CDK2). Consistent with this ability to regulate the cell cycle, GNPs resulted in sensitization to ionizing radiation. Collectively, these results suggest that GNPs may function in anticancer therapy as a radiotherapeutic sensitizer. These results also imply a previously unexplored activity of GNPs to inhibit p53 and cyclin A, and activate cyclin E and cyclin B1.
Materials and methods

Chemicals
All chemicals were obtained from Sigma-Aldrich (Milwaukee, WI). The MTT CellTiter 96 non-radioactive cell proliferation assay kit was purchased from Promega (Madison, WI).
Synthesis of gold nanoparticles
The general method for synthesizing gold nanoparticles has been previously described [18] .
Fluoro-6-deoxythio-1-D-glucose (Glu) covalently bound to the GNPs to form functionalized Glu-capped gold nanoparticles (GluGNPs) [18] .
The Glu-GNPs were characterized using transmission electronic microscopy (TEM), ICP-MS and Kratos Axis 165 x-ray photoelectron spectroscopy (XPS) (Kratos Analytical) as described previously [18] .
Cell culture
The human prostate carcinoma cell line DU-145 and human diploid fibroblast cell line MRC5 were purchased from the American Type Culture Collection (Manassas, VA, USA). These cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 20 mM D-glucose, 100 UI ml −1 penicillin G, and 100 μg ml
streptomycin in a humidified incubator with 5% CO 2 in the air at 37
• C. DMEM without glucose was utilized when the cells were exposed to Glu-GNPs.
Uptake assay
All assays were performed in triplicate. When the cells reached 70% confluence, the target cells were exposed to the vehicle, or 15 nM Glu-GNPs at 37
• C. After 1, 2, 4, 6, 18, and 24 h of incubation, the free GNPs in the cell cultures were removed by washing the plated cells twice with the PBS buffer. The number of cells was counted with a hemocytometer. Five ml of 50% HNO 3 was added to each sample to lyse the cells. The gold mass in each solution was measured using inductively coupled plasma mass spectrometry (ICP-MS). The number of gold nanoparticles was calculated via the gold mass, and the number of GNPs in the lysis solution was divided by the number of cells to yield the number of GNPs taken up per cell [18] .
Irradiation (IR) of cells and clonogenic survival assay
All treatments were carried out in triplicate and repeated. Ionizing radiation treatments were carried out using a Shephard 81-14R cesium-137 (Cs-137) beam irradiator (J L Shepard, San Fernando, CA) at a dose rate of 1.32 Gy min −1 . DU145 cells in 100 mm culture dishes were irradiated at room temperature where the cultures reached 75% confluence. Cells received either a mock treatment for control, GNPs, 2 Gy, GNPs (5-20 nM) plus 2 Gy or GNPs (15 nM) plus cytochalasin B (10 μm) and 2 Gy. After IR, cultures were incubated in 5% CO 2 at 37
• C until they were harvested at the fixed time points. For clonogenic survival assay, harvested cells were re-suspended and plated at known numbers. Colonies were allowed to form with 10-14 days of incubation. Visible colonies were counted, with a colony considered to be at least 50 cells. The surviving cell fraction was normalized to the survival of the control cells. Radiation survival curves were constructed by normalizing the number of surviving colonies after combined treatment to the number of surviving colonies following treatment with tachpyridine alone, and the curves fitted by second-order linear regression. The dose enhancement ratio (DER) was attained by clonogenic survival assay, and calculated as the ratio of radiation doses required to give the same biological effect (surviving fraction) in the absence or the presence of Glu-GNPs.
MTT assay.
Assessment of the cellular response to Glu-GNPs with and without radiation was determined using MTT assay following the manufacturer's instructions (Roche Diagnostics, Indianapolis, IN). The experiments were performed in replicates of eight. To determine whether GNPs enhanced the radio-sensitivity of DU-145 cells to IR, cells were treated with either irradiation, Glu-GNPs alone, or Glu-GNPs plus irradiation. Untreated control samples were arbitrarily assigned a value of 100% and the results of all treatments were normalized to the control group. The cell growth inhibitory rate was calculated by the following formula: inhibitory rate = (1 − average OD 550 nm of treated group/average OD 550 nm of the control group) × 100%.
Western blot analysis
The lysed cell samples with a protein content of at least 35 μg were separated by sodium dodecyl sulfate (SDS)-10% polyacrylamide gel, and then transferred onto nitrocellulose. The membranes were blocked with 5% skimmed milk in a TBS-Tween buffer (TBS-T) and incubated with 8 ml of mouse anti-p53 antibody (1/1000; Abcam ab26), mouse anti-cyclin B1 antibody (1/1000; Abcam ab72), rabbit anticyclin A antibody (1/200; Abcam ab7956), rabbit anti-cyclin E antibody (1/200; Abcam ab7959) and β-actin (1/2000) for 1 h. HRP-conjugated secondary goat-anti-rabbit and goatanti-mouse antibodies were used at a dilution of 1:6000 and protein bands were analyzed using the Super Signal West Pico Chemiluminescence Substrate (Thermo Scientific, IL61101, USA). Proteins were quantified densitometrically with Photoshop software to calculate the ratios of each protein to its corresponding β-actin protein.
Flow cytometry analysis of cell cycle
The cells fixed in 70% ethanol were washed, re-suspended and treated with 10 μg ml −1 RNase for 30 min at 37
• C, and then stained with PBS containing 50 μg ml −1 PI for 30 min at 4 • C. Analysis was performed with a FACSCalibur flow cytometer (Becton-Dickinson, BD Biosciences, Ontario, Canada). These tests were performed in triplicate and each 20 000 cell sample was tested. The data on cellular DNA content and cell cycle were analyzed by CellQuest and ModFit LT software (Verity Software House, Inc., Topsham, ME, USA). Values were expressed as the mean ± standard deviation (SD).
Ratio of cell cycle changes in G2-M/G0/G1 (RCGG)
A parameter termed RCGG, to represent cell status at the time of radiotherapy, was derived based on the measured cell cycle changes with GNP treatment. As G0/G1 is the phase that is most resistant and G2/M is the phase that is most sensitive to radiotherapy, the cellular radio-sensitivity depends on the changes in these two cell cycle phases. The RCGG is calculated by:
Several features of the RCGG can be derived: (i) a larger value of G2/M leads to larger RCGG; (ii) a larger value of G0/G1 (%) leads to smaller RCGG; and (iii) a larger RCGG implies cells are more sensitive to radiotherapy.
Statistical analysis
Differences between the treated and control groups were compared using Student's t-tests, with the differences at the p < 0.05 level considered to be statistically significant.
Results
Distribution and uptake of GNPs on DU-145 cells
Glu-GNPs, that are synthesized by binding fluoro-6-deoxy-Dglucose (Glu) (A) on gold nanoparticles (GNPs, 10.8 nm) (B), are shown in the transmission electron microscopy (TEM) images (figure 1(C)) and schematic diagram (D). After DU-145 cells (E) were treated with 15 nM naked GNPs (TGSGNPs), or Glu-GNPs for 2 h, the average number of GNPs associated with each cell was (2.06 ± 0.24) × 10 4 for naked GNPs, and (6.3±0.67)×10 4 for Glu-GNPs (figure 1(G)). Most Glu-GNPs were distributed inside the cytoplasm ( figure 1(F) ). After exposure to 15 nM Glu-GNPs for 1, 2, 4, 6, 18 and 24 h, the average numbers of Glu-GNPs taken up by each DU-145 cell per time interval are illustrated in figure 1(H) . The average number of GNPs increased with time and peaked at 4 h at (7.03 ± 0.27) × 10 4 .
Glu-GNPs enhanced radiation sensitivity
At 24 h, Glu-GNPs and 2 Gy Cs137 γ -ray IR induced inhibition of cell proliferation of 8.2% and 7.4%, respectively. However, the combination of Glu-GNPs and IR inhibited cell proliferation in DU-145 by 26.8% (P < 0.005) ( figure 2(A) ). The dose-dependent effects induced by various concentrations of Glu-GNPs on 2 Gy IR are shown in figure 2 (B). Cytochalasin B, an inhibitor of glucose transport receptor I, partially reversed the enhancement on the radiotherapy induced by Glu-GNPs, with an inhibition 13.8%. The clonogenic cell survival assay was also used to determine whether Glu-GNPs enhanced radiation sensitivity. Two Gy Cs137 γ -ray IR had no effect on cell survival (figure 2(C)) with a 102.0% cell survival rate after 14 days. However, when the cells were exposed to Glu-GNPs for 2 h, then 2 Gy Cs137 γ -ray IR, the cell survival rate at 14 days dropped to 36.0% ( figure 2(C) ). Similar results were identified for apoptosis as measured by flow cytometry ( figure 2(D) ).
Glu-GNPs do not enhance the sensitivity of non-cancerous cells to irradiation
To assess potential effects of radiation on normal cells treated with Glu-GNPs, MRC5 human diploid fibroblasts were compared with DU-145 cells. Both cell lines had comparable growth rates. Figures 2(A) and (B) demonstrate that 2 Gy Cs-137 γ -ray IR induced 7.4% and 18.7% inhibition rates in the DU-145 and MRC5 cell viabilities, respectively. Following 2 h incubation with Glu-GNPs and IR, the cell viability of DU-145 cells was further decreased, with a 26.8% inhibition rate. The corresponding cell viability of MRC5 fibroblasts treated with Glu-GNPs and IR showed no significant change. These results demonstrate that Glu-GNPs only enhanced the radiation sensitivity of cancer cells, but had no observed effect on nonmalignant fibroblasts.
Glu-GNPs alter cell cycle distribution
Treatment of DU-145 cells with 15 nM Glu-GNP for 2 h induced an increase of cells in the G2/M phase and a decrease of cells in the G0/G1 phase when compared with the control cells (figures 3(A)-(D)
). GNPs arrested cells at G2/M, the radio-sensitive phases of the cell cycle, and thereby enhanced the radiation sensitivity of DU-145 cells. In this study, 18.4% of untreated control cells were in the G2/M phase and Glu-GNP increased the fraction of cells in the G2/M phase to 29.8% ( p < 0.05) ( figure 3(E) ). When compared to Cs137 γ -ray IR and Glu-GNP alone, there was a significant increase in the fraction of G2/M (40.5%) in the Glu-GNPs plus irradiation combination ( p < 0.05) ( figure 3(H) ). The Glu-GNPs alone and Glu-GNPs combined with irradiation samples showed decreases in the fraction of cells in the G0/G1 phase from 58.9% for the control to 43.2% and 38.1% respectively ( p < 0.05) ( figure 3(F) ).
The role of p53 in Glu-GNPs mediated cell cycle distribution
Both Cs137 IR and Glu-GNPs induced a significant decrease in p53 expression in DU-145 prostate cancer cells. Notably, the expressible intensities of p53 in the DU-145 cells were distinct in their response to GNPs, Cs-137 IR or Glu-GNPs plus Cs-137 IR (figure 4). Compared to the control, cells treated with either Glu-GNPs or Cs-137 IR exhibited a decreased expression of p53 protein, with a transient inhibition during the first 24 h, followed by gradual recovery (figures 4(A) and (B)). After DU-145 cells were exposed to Glu-GNPs for 2 h and then 2 Gy of Cs-137 IR, the expression of p53 was inhibited by 95.0% in the first 24 h, followed by a recovery to 29.1% in expressible intensity in 48 h.
Changes in cyclins in Glu-GNP mediated cell cycle arrest
To explore the mechanism of Glu-GNP mediated cell cycle changes, we tested the involvement of checkpoint activations. The cell samples were analyzed by western blotting using specific antibodies against the activated cyclin B1, cyclin A and cyclin E proteins that are involved in either CDK1 or CDK2 kinases. Glu-GNPs activated proteins for both kinases as follows. Cyclin B1/CDC2 is an important kinase for the regulation of the G2 to M transition [21, 22] . Figures 4(A) and (B) indicate that either Glu-GNPs or Cs-137 γ -ray induced a significant increase in the expressible cyclin B1 intensity (1.9 fold and 2.7 fold in 24 h, and 1.6 fold and 1.3 fold in 48 h, respectively). After treatment with Glu-GNPs plus Cs137 γ -ray IR, the expression of cyclin B1 was increased by 8.0 fold at 24 h and 1.7 fold at 48 h when compared to the control.
Cyclin A regulates at least two CDKs, CDK1 and CDK2, and is believed to be necessary for progression through the S phase and the G2-M transition [20, [22] [23] [24] [25] [26] . After treatment with either Glu-GNPs or Cs-137 γ -ray IR, the expressible intensities of cyclin A were at 24 h significantly reduced by 84.5% with Cs137 or 42.3% with Glu-GNPs. Combined GluGNPs and IR resulted in a 97.7% inhibition of cyclin A protein at 24 h. The cyclin A inhibition induced by the combination of Glu-GNPs and IR recovered to 60.2% at 48 h ( figure 4(B) ).
Cyclin E is a G1 cyclin that has been shown to be one of the key regulators of the G1-S transition [22] . Cyclin E binds to CDK2, forming the cyclin E/CDK2 complex, which pushes the cell from the G1 to the S phase (G1/S transition). GluGNPs increased the expression of cyclin E by 1.2 fold at 24 h and by 1.5 fold at 48 h. Combination therapy of Glu-GNPs for 2 h, followed by 2 Gy Cs-137 γ -ray IR, increased cyclin E expression by 4.2 fold at 48 h ( figure 4(B) ).
Cell cycle guided optimal time schedule of radiotherapy
Because G0/G1 is the phase that is most resistant and G2/M is the phase that is most sensitive to radiotherapy, the RCGG value that represents the changes in both G0/G1 and G2/M was derived to represent cell status to radiotherapy [27, 28] . The dynamic changes in RCGG values induced by Glu-GNPs are showed in figure 5. After treatment with Glu-GNPs for incremental time intervals, the RCGG values in DU-145 cells were 0.23, 0.28, 0.46, and 0.25 for 2, 4, 6 and 20 h, respectively. Based on the RCGG values produced by incremental Glu-GNPs exposure, we examined the radiation sensitivities with clonogenic survival assay. Treatment with Glu-GNPs for 2 h and 6 h resulted in DERs of 1.24 and 1.38, respectively ( p < 0.05).
Discussion
The potential application of gold nanoparticles in the treatment of human diseases is an area of active investigation. There have been reports of GNPs used for phototherapy being taken up in greater quantities by malignant cells, and producing equal cell killing with half the laser energy [16, 17] . However, because of the poor penetration of laser light, phototherapy is ineffective in treating many cancers. Thus, research has focused on how GNPs can enhance IR, an energy source that can easily reach deep tissue. Several studies have demonstrated the enhancement of x-rays or γ -rays by GNPs, both in vitro and in vivo. We have demonstrated that GNPs can significantly increase the radio-sensitivity of prostate cancer cells [19] . An understanding of the mechanism of action of GNPs may be beneficial in optimizing their efficacy, as well as providing fundamental insights into the nature of intracellular targets. Here, we explored the mechanism of how GNPs increased the sensitivity of DU-145 cells to radiotherapy.
We demonstrated that GNPs accelerated the G1/S phase of the cell cycle and arrested the cells in the G2/M phase. To the best of our knowledge, this is the first report on how GNPs effect the regulation of the cell cycle to sensitize DU-145 cancer cells to radiotherapy. p53, cyclin E, cyclin A and cyclin B1 were critical mediators of the GNP-induced cell cycle changes. We also provide evidence that selective cancer cell sensitization to IR is the consequence of GNP mediated G2/M arrest. A working schematic model for the mechanism of cell cycle changes induced by GNPs is shown in figure 6 . Based on the observed cell cycle kinetics data, the highest radio-sensitivity was achieved when IR was administered at the time point of 6 h, at the greatest RCGG ratio. Since G0/G1 is the cell cycle phase that is most resistant to radiotherapy and G2/M is the phase that is most sensitive, one mechanism by which Glu-GNP enhances radiotherapy sensitivity is cell cycle regulation.
The studies on cell cycle checking kinases also support the results of cell cycle changes induced by Glu-GNPs. Figure 4 shows a significantly increased expression of cyclin E and cyclin B1, and decreased expression of cyclin A. Cyclin E is a G1 cyclin that has been shown to be one of the key regulators of the G1-S transition. Cyclin E binds to CDK2, forming the cyclin E/CDK2 complex, which pushes the cell from the G1 to the S phase (G1/S transition) [28] [29] [30] . GluGNPs inhibited expression of cyclin E to accelerate the G0/G1 phase and in turn to accumulate cells in the G2/M phase. After Glu-GNP treatment, the expression of cyclin B1 by DU-145 cells was significantly increased (P < 0.05). The increase in cyclin B1 results from cell accumulation in the G2/M phase. Therefore, cell accumulation in the G2/M phase induced by Glu-GNPs is different from cell arrest in the G2/M phase induced by DNA damage. DNA damage induces increased p53 expression to inhibit cyclin B1 expression and cause cell arrest in the G2/M phase. In this study, Glu-GNPs inhibited p53 expression, resulting in cyclin E overexpression, which shortens the G1/S transition. Furthermore, Glu-GNPs induced cell accumulation in the G2/M phase via the acceleration of the G0/G1 phase. Increased cyclin B1 expression is a marker of cell accumulation in the G2/M phase. One function of p53 is to decompose cyclin B1. When the expression of p53 was inhibited by GNPs, a weaker decomposability induced accumulation of cyclin B1. As an S phase complex, the major function of cyclin A is to regulate the S phase. However, cyclin A/CDK2 has also been implicated in mitosis [23] [24] [25] . Microinjection of cyclin A/CDK2 can promote mitotic entry of human G2 phase cells. Conversely, the injection of cyclin A specific antibodies after the S phase prevented human cells from progressing through mitosis [26] . In this study, GluGNPs inhibited cyclin A expression by 42.3%. Cyclin A along with CDK2 forms the cyclin A-CDK2 complex, which initiates the G2/M transition. Inhibition of cyclin A induced a delay of the G2/M transition.
The concept of synchronizing tumor cells in a cell cycle phase that is sensitive to radiation is recognized as a potentially important way to enhance the clinical efficacy of radiotherapy [27] [28] [29] . Thus there are potentially important clinical ramifications of our findings, given that the G2/M phase of the cell cycle is the most sensitive to IR [30, 31] . Importantly, the radio-sensitivity of non-cancer fibroblast cells to IR was not similarly enhanced. In addition, the dose enhancement ratios derived from radiation survival curves with GNP were comparable to those reported in the literature for clinically useful radio-sensitizers. Our experiments therefore provide evidence that the GNPs are an effective sensitizer for prostate cancer radiotherapy. In our laboratory, we modified the surface of GNPs with glucose. The efficacy of sensitized radiotherapy was Glu-GNPs dose-dependent ( figure 2(B) ). Cytochalasin B, an inhibitor of glucose transport receptor I, partially reversed the enhancement on the radiotherapy induced by Glu-GNPs ( figure 2(A) ). This result gives an explanation how glucose improved gold nanoparticle delivery to enhance radiation sensitivity. However, the mechanism of the interaction between Glu-GNPs and glucose transporter needs further investigation.
The role of the cell cycle phase is believed to be critical to the mechanism of action of both radiotherapeutics and other therapeutic agents [32, 33] . When a therapeutic agent, e.g. GNPs, is used to accumulate cells in the G2/M phases, and reduce cells in the G0/G1 phase, it will lead to increased radio-sensitivity [34, 35] . The level of cellular uptake of GNPs and cell cycle changes induced by GNPs are time dependent and different between cancerous and non-cancerous cells, resulting in variable levels of enhancement of radiosensitivity. Given this, a 'kinetic' approach will be needed for GNP enhanced radiotherapy, with the emphasis on the need for the appropriate timing of GNP administration. We evaluated the correlation between the dynamic behaviors of cell cycle changes, including accelerating cells in the G0/G1 phase and arresting cells in the G2/M phase, presented through RCGG induced by Glu-GNPs and radiotherapy cytotoxicity, with various Glu-GNPs exposure time periods. Generally, a larger value of RCGG should lead to a more sensitive radiotherapy. Indeed, the maximal IR sensitization induced by GNPs occurred at 6 h, when the highest RCGG value was achieved. Thus, the in vitro RCGG value may have utility to optimize the time schedule of post-Glu-GNPs administration of IR to maximize radiation sensitivity. Further in vitro and in vivo studies are underway to evaluate this.
In summary, we are the first to report that Glu-GNPs trigger activation of the CDK kinases leading to cell cycle accumulation in the G2/M phase and acceleration in the G0/G1 phase. This is accompanied by a striking sensitization to ionizing radiation, which may have clinical implications. Taking into consideration the time dependence of the cell cycle changes induced by GNPs, an optimized radiation sensitivity was obtained. These studies suggest for the first time that p53 and the CDK kinases are targets for gold nanoparticles.
